
Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Stock Performance (90 Days)
Layoff History
Earnings Call Transcripts
View All →Abbott Laboratories' Q4 2025 announcement, referencing Q3 results, details its non-GAAP financial reporting methodology. The provided text lacks specific Q4 2025 financial figures like revenue or EPS, making a performance analysis impossible.
Abbott's Q2 2025 announcement primarily discusses its use of non-GAAP financial measures, referring to Exhibit 99.1 for specific results. Key financial figures like revenue and EPS are not detailed in this release, preventing a quantitative summary.
Abbott Laboratories' Q2 2025 announcement details its use of non-GAAP financial measures, adjusting for unusual items. However, it notably omits specific revenue, earnings, or EPS figures for the quarter, preventing a quantitative performance assessment.
Abbott Laboratories announced its Q4 and full year 2024 results on January 22, 2025. The provided text, however, does not contain specific financial figures for Q4 2024 or Q1 2025, preventing a detailed analysis of performance.
Recent News
Other Medical Devices Companies
View All →Frequently Asked Questions
Has ABBOTT LABORATORIES had layoffs?
How many employees does ABBOTT LABORATORIES have?
What industry is ABBOTT LABORATORIES in?
Is ABBOTT LABORATORIES a publicly traded company?
Where is ABBOTT LABORATORIES headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.